secwatch / observer

8-K filed May 18, 2026 13:06 UTC ticker SLNO CIK 0001484565

m_and_a confidence high sentiment neutral materiality 1.00

Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each

SOLENO THERAPEUTICS INC

Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.
Stockholders received $53.00 per share in cash; total offer consideration funded via Neurocrine cash.
All pre-merger directors and officers resigned; new directors and officers from Neurocrine appointed.
Shares to be delisted from Nasdaq and deregistered with SEC; Form 15 to be filed.
Loan agreement with Oxford Finance and 2014 ESPP terminated effective upon merger.

item 1.02item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Patricia Hirano

Senior Vice President, Regulatory Affairs

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Departed

Mark Hahn

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors

Departed

Andrew Sinclair

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors

Departed

Anish Bhatnagar

Chief Executive Officer

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Departed

Anish Bhatnagar

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors

Departed

Kristen Yen

Senior Vice President, Global Clinical Operations & Patient Advocacy

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Appointed

Darin M. Lippoldt

President and Secretary

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).

Departed

Matthew Pauls

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors

Departed

Jennifer Fulk

Chief Financial Officer

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Departed

Kevin Norrett

Chief Business Officer

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Appointed

Matthew C. Abernethy

Treasurer and Vice President

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).

Appointed

Matthew C. Abernethy

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company

Departed

Meredith Manning

Chief Commercial Officer

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Departed

Manher (AJ) Joshi

Chief Development Officer

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Departed

Birgitte Volck

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors

Departed

Michael Huang

Senior Vice President, Clinical Development

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer

Appointed

Darin M. Lippoldt

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company

Departed

Dawn Bir

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2026-05-18
Filed: May 18, 2026 13:06 UTC

each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors

Source: SEC EDGAR

accession 0001193125-26-228016

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.